Dr Paul Varley

Paul Varley Chief Development Officer, Alchemab Therapeutics.

Dr Varley is an expert in biopharmaceutical development with more than 30+ year’s experience of developing antibodies, and other biological medicines from research into the clinic and through to commercialization. Paul is currently Chief Development Officer at Alchemab Therapeutics in Cambridge UK. Previously Paul held  similar roles in Cambridge Antibody Technology, Astra Zeneca, MedImmune and most recently Kymab. Previously Paul had also worked at British Biotech, the UK National Institute of Biological Standards and Control (NIBSC) and the U.S. National Institutes of Health. Dr Varley holds a degree in Biomolecular Sciences (First Class) from Portsmouth Polytechnic and a PhD in Biochemistry from the University of Newcastle upon Tyne.

Until recently Paul was a member of the British Pharmacopeia (BP) Commission and Chair of BP Expert Advisory Group on Biological and Biotechnological Products (2013 – 2022). He also currently chairs a MHRA/BP working party on new standards for Biological Medicines (DPS) and is a member of the European Pharmacopeia (EP) Expert Committee on Monoclonal Antibodies.

Paul was also a founder member if the UK BIA COVID-19 Antibody Task Force which recently spun out as RQ Biotech and was a member of the UK Vaccines Task Force.

Paul is member the SAB of Spirea and Spliceor and has contributed to many Advisory Boards and related activities during his career including at University Cambridge Department of Chemical Engineering and Biotechnology, University College London Biochemical Engineering, the UK National Biologics Manufacturing Centre and the White Rose Universities DTP in Mechanistic Biology. Paul has also been involved with many other activities in the Biopharmaceutical / Bioprocessing space including the European Biotech Enterprises (EBE) Biomanufacturing Committee, Bioprocess UK steering group, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Biotherapeutics group, and BioProNet.

Paul acts an advisory consultant to multiple biotech’s, typically in the start up / early development phase with a strong focus on product development strategy and line of site to development and commercialization.